BioNTech与百时美施贵宝合作开发癌症药物 - 老虎社区

资讯资讯
帖子帖子
精选精选

- 荷马先生荷马先生
  ·06-02
  Summit已经领先的
  BioNTech将与百时美施贵宝合作开发创新型抗癌药物
  合作开发一种创新型抗癌药物BNT327。
  BioNTech将与百时美施贵宝合作开发创新型抗癌药物
  177 评论
  1
  分享
  举报
- 荷马先生荷马先生
  ·06-02
  Summit已经领先的
  BioNTech将与百时美施贵宝合作开发创新型抗癌药物
  合作开发一种创新型抗癌药物BNT327。
  BioNTech将与百时美施贵宝合作开发创新型抗癌药物
  177 评论
  1
  分享
  举报

{"themeInfo":{"themeId":"69ca1192f62d6fb77c0cc6cb23935843","name":"BioNTech与百时美施贵宝合作开发癌症药物","description":"BioNTech与百时美施贵宝达成全球战略合作伙伴关系，共同开发和共同商业化用于多种实体瘤类型的下一代双特异性候选抗体BNT327。该协议涉及百时美施贵宝向BioNTech支付最多111亿美元，首期付款15亿美元。此次合作旨在加速临床试验进程，潜在扩大治疗适应症，为癌症患者提供新的治疗选择。","image":"https://static.tigerbbs.com/1201dcc0482be040348fb8d4f228bb68","type":2,"style":4,"follow":false,"createTime":1748863527568,"userCounts":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/special/finance&rndata={\"themeId\":69ca1192f62d6fb77c0cc6cb23935843}&rnconfig={\"headerBarHidden\": true}","subscribe":false,"allowFollow":false,"hasReward":false,"rewardScore":0,"rewardValidDate":0,"rewardEnd":false,"symbols":["BNTX","MYE"],"tweetCounts":1,"categoryId":"2929bb7468f5415f853fd96fb35d7c3b","options":[],"votedOptionId":"","totalUserCount":0,"followStatus":false,"themeName":"BioNTech与百时美施贵宝合作开发癌症药物","tweetAmount":1,"imageIsDefault":true},"tab":"all","isFinancial":true,"allList":[{"id":441677922571136,"gmtCreate":1748870129607,"gmtModify":1748870130711,"author":{"id":"3570605047103152","authorId":"3570605047103152","name":"荷马先生","avatar":"https://static.tigerbbs.com/1d69283377af06639e7c3544aa273e68","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3570605047103152","authorIdStr":"3570605047103152"},"themes":[],"htmlText":"Summit已经领先的","listText":"Summit已经领先的","text":"Summit已经领先的","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/441677922571136","repostId":"1153113028","repostType":4,"repost":{"id":"1153113028","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1748863530,"share":"https://www.laohu8.com/m/news/1153113028?lang=&edition=full","pubTime":"2025-06-02 19:25","market":"us","language":"zh","title":"BioNTech将与百时美施贵宝合作开发创新型抗癌药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1153113028","media":"老虎资讯综合","summary":"合作开发一种创新型抗癌药物BNT327。","content":"<html><head></head><body><p>消息显示，美国制药巨头百时美施贵宝（Bristol Myers Squibb）将与BioNTech合作开发一种创新型抗癌药物BNT327。根据协议，百时美施贵宝将向BioNTech支付15亿美元的预付款，整个合作项目的总价值可能超过110亿美元。这笔交易不仅为BioNTech带来了可观的即时现金流，还为其癌症研究领域的发展提供了强有力的支持。</p><p style=\"text-align: start;\">BNT327是一种新一代免疫疗法，属于双特异性抗体类药物，主要针对PD-L1和VEGF-A这两种蛋白。目前，该药物正在进行广泛期小细胞肺癌和非小细胞肺癌的一线治疗测试。根据合作协议，两家公司将共同开发和商业化BNT327，平分全球利润和亏损，共同承担开发和生产成本。</p><p style=\"text-align: start;\">这一合作不仅有望加快BNT327的临床试验进程和上市时间，还可能扩大其潜在的适应症范围，为癌症患者带来新的治疗希望。</p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/eded2de1312c9f898c1ff12fb66f513d\" tg-width=\"560\" tg-height=\"240\"/></p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech将与百时美施贵宝合作开发创新型抗癌药物</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech将与百时美施贵宝合作开发创新型抗癌药物\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2025-06-02 19:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>消息显示，美国制药巨头百时美施贵宝（Bristol Myers Squibb）将与BioNTech合作开发一种创新型抗癌药物BNT327。根据协议，百时美施贵宝将向BioNTech支付15亿美元的预付款，整个合作项目的总价值可能超过110亿美元。这笔交易不仅为BioNTech带来了可观的即时现金流，还为其癌症研究领域的发展提供了强有力的支持。</p><p style=\"text-align: start;\">BNT327是一种新一代免疫疗法，属于双特异性抗体类药物，主要针对PD-L1和VEGF-A这两种蛋白。目前，该药物正在进行广泛期小细胞肺癌和非小细胞肺癌的一线治疗测试。根据合作协议，两家公司将共同开发和商业化BNT327，平分全球利润和亏损，共同承担开发和生产成本。</p><p style=\"text-align: start;\">这一合作不仅有望加快BNT327的临床试验进程和上市时间，还可能扩大其潜在的适应症范围，为癌症患者带来新的治疗希望。</p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/eded2de1312c9f898c1ff12fb66f513d\" tg-width=\"560\" tg-height=\"240\"/></p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/c262c3da2bb785b214c4d9cb77e12535","relate_stocks":{},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153113028","content_text":"消息显示，美国制药巨头百时美施贵宝（Bristol Myers Squibb）将与BioNTech合作开发一种创新型抗癌药物BNT327。根据协议，百时美施贵宝将向BioNTech支付15亿美元的预付款，整个合作项目的总价值可能超过110亿美元。这笔交易不仅为BioNTech带来了可观的即时现金流，还为其癌症研究领域的发展提供了强有力的支持。BNT327是一种新一代免疫疗法，属于双特异性抗体类药物，主要针对PD-L1和VEGF-A这两种蛋白。目前，该药物正在进行广泛期小细胞肺癌和非小细胞肺癌的一线治疗测试。根据合作协议，两家公司将共同开发和商业化BNT327，平分全球利润和亏损，共同承担开发和生产成本。这一合作不仅有望加快BNT327的临床试验进程和上市时间，还可能扩大其潜在的适应症范围，为癌症患者带来新的治疗希望。","news_type":1,"symbols_score_info":{"BNTX":1.1}},"isVote":1,"tweetType":1,"viewCount":177,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"essenList":[{"id":441677922571136,"gmtCreate":1748870129607,"gmtModify":1748870130711,"author":{"id":"3570605047103152","authorId":"3570605047103152","name":"荷马先生","avatar":"https://static.tigerbbs.com/1d69283377af06639e7c3544aa273e68","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3570605047103152","authorIdStr":"3570605047103152"},"themes":[],"htmlText":"Summit已经领先的","listText":"Summit已经领先的","text":"Summit已经领先的","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/441677922571136","repostId":"1153113028","repostType":4,"repost":{"id":"1153113028","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1748863530,"share":"https://www.laohu8.com/m/news/1153113028?lang=&edition=full","pubTime":"2025-06-02 19:25","market":"us","language":"zh","title":"BioNTech将与百时美施贵宝合作开发创新型抗癌药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1153113028","media":"老虎资讯综合","summary":"合作开发一种创新型抗癌药物BNT327。","content":"<html><head></head><body><p>消息显示，美国制药巨头百时美施贵宝（Bristol Myers Squibb）将与BioNTech合作开发一种创新型抗癌药物BNT327。根据协议，百时美施贵宝将向BioNTech支付15亿美元的预付款，整个合作项目的总价值可能超过110亿美元。这笔交易不仅为BioNTech带来了可观的即时现金流，还为其癌症研究领域的发展提供了强有力的支持。</p><p style=\"text-align: start;\">BNT327是一种新一代免疫疗法，属于双特异性抗体类药物，主要针对PD-L1和VEGF-A这两种蛋白。目前，该药物正在进行广泛期小细胞肺癌和非小细胞肺癌的一线治疗测试。根据合作协议，两家公司将共同开发和商业化BNT327，平分全球利润和亏损，共同承担开发和生产成本。</p><p style=\"text-align: start;\">这一合作不仅有望加快BNT327的临床试验进程和上市时间，还可能扩大其潜在的适应症范围，为癌症患者带来新的治疗希望。</p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/eded2de1312c9f898c1ff12fb66f513d\" tg-width=\"560\" tg-height=\"240\"/></p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech将与百时美施贵宝合作开发创新型抗癌药物</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech将与百时美施贵宝合作开发创新型抗癌药物\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2025-06-02 19:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>消息显示，美国制药巨头百时美施贵宝（Bristol Myers Squibb）将与BioNTech合作开发一种创新型抗癌药物BNT327。根据协议，百时美施贵宝将向BioNTech支付15亿美元的预付款，整个合作项目的总价值可能超过110亿美元。这笔交易不仅为BioNTech带来了可观的即时现金流，还为其癌症研究领域的发展提供了强有力的支持。</p><p style=\"text-align: start;\">BNT327是一种新一代免疫疗法，属于双特异性抗体类药物，主要针对PD-L1和VEGF-A这两种蛋白。目前，该药物正在进行广泛期小细胞肺癌和非小细胞肺癌的一线治疗测试。根据合作协议，两家公司将共同开发和商业化BNT327，平分全球利润和亏损，共同承担开发和生产成本。</p><p style=\"text-align: start;\">这一合作不仅有望加快BNT327的临床试验进程和上市时间，还可能扩大其潜在的适应症范围，为癌症患者带来新的治疗希望。</p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/eded2de1312c9f898c1ff12fb66f513d\" tg-width=\"560\" tg-height=\"240\"/></p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/c262c3da2bb785b214c4d9cb77e12535","relate_stocks":{},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153113028","content_text":"消息显示，美国制药巨头百时美施贵宝（Bristol Myers Squibb）将与BioNTech合作开发一种创新型抗癌药物BNT327。根据协议，百时美施贵宝将向BioNTech支付15亿美元的预付款，整个合作项目的总价值可能超过110亿美元。这笔交易不仅为BioNTech带来了可观的即时现金流，还为其癌症研究领域的发展提供了强有力的支持。BNT327是一种新一代免疫疗法，属于双特异性抗体类药物，主要针对PD-L1和VEGF-A这两种蛋白。目前，该药物正在进行广泛期小细胞肺癌和非小细胞肺癌的一线治疗测试。根据合作协议，两家公司将共同开发和商业化BNT327，平分全球利润和亏损，共同承担开发和生产成本。这一合作不仅有望加快BNT327的临床试验进程和上市时间，还可能扩大其潜在的适应症范围，为癌症患者带来新的治疗希望。","news_type":1,"symbols_score_info":{"BNTX":1.1}},"isVote":1,"tweetType":1,"viewCount":177,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"allBottom":false,"essenBottom":false,"topicSource":"Post"}